A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

July 10, 2020

Study Completion Date

July 10, 2020

Conditions
Primary MyelofibrosisPolycythemia VeraPost-Essential Thrombocythemia Myelofibrosis
Interventions
BIOLOGICAL

RO7490677

IV infusion

DRUG

Ruxolitinib

IV infusion

Trial Locations (23)

10029

Mount Sinai Medical Center, New York

10065

Weill Cornell Medical Center, New York

21201

University of Maryland Medical Center, Baltimore

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

27157

Wake Forest Baptist Medical Center, Winston-Salem

30322

Emory Hospital, Atlanta

32429

Johannes Wesling Academic Medical Center, Minden

37232

Vanderbilt University Medical Center, Nashville

61122

Marche Nord Hospital, Pesaro

75475

Hospital Saint-Louis, Paris

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic Cancer Center, Phoenix

91120

Hadassah Medical Centre, Jerusalem

94304

Stanford Cancer Institute, Palo Alto

4428164

Meir Medical Centre, Kfar Saba

02215

Dana-Farber Cancer Institute, Boston

48109-2800

University of Michigan, Ann Arbor

V6Z 2A5

Providence Health Care, Vancouver

M5T 2M9

The Princess Margaret Cancer Centre, Toronto

D-52074

University Medical Center RWTH Aachen, Aachen

3015 CE

Erasmus Medical Center, Rotterdam

6525 GA

Radboud University Medical Center, Nijmegen

Unknown

Guy's and St. Thomas' Hospital, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01981850 - A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | Biotech Hunter | Biotech Hunter